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1. GENERAL INTRODUCTION 
1.1    Breast cancer   
The high incidence of cancer in both developed and developing countries is a remarkable 
leading cause of global death. Breast cancer prevalence is estimated at 23% and 14% mortality 
among total cancers accounting for female cancers worldwide1.  The high incidence of breast 
cancer is mainly associated with hormonal factors and adaption of western life style including 
physical inactivity, obesity and late age at first birth2, 3. The mortality rate of breast cancer has 
markedly decreased with the advantage of mammography and the utilization of advanced 
treatment strategies 4; however, more detection methods such as novel biomarkers and new 
therapeutic strategies are needed to be developed. 
1.1.1    Breast cancer subtypes  
Classification of breast cancer into subtypes is primarily used to aid in treatment and 
prognosis. Breast cancer is generally categorized into two main histopathological classes, in situ 
carcinoma and invasive/infiltrating carcinoma. In situ carcinoma is further classified into two 
subtypes as Ductal carcinoma in situ (DCIS), the most common form of breast cancer, and 
lobular carcinoma in situ (LCIS), which encompasses a heterogeneous group of tumors. 
Invasive/infiltrating carcinoma is divided to seven subtypes as illustrated in Table 15. 
In addition to the conventional histologic parameters, classification based on molecular 
components has been described with greater prognostic values for managing target therapy in 
breast cancer. Molecular subtypes of breast cancer are categorized as basal-like, ErbB2+, normal 
breast like, luminal subtype A and luminal subtype B, and claudin low. These subtypes could 










































































































































Table.1 Histological classification of breast cancer subtypes. 
Breast cancer Sub-types 











1.1.2    Lymph node metastasis 
Invasion and metastasis are important hallmarks of malignant tumors associated with 
complex genetics and epigenetic alterations that allow tumors to disseminate throughout 
lymphatic or blood vessels, giving rise to the colonization and growth of metastatic cells in 
distant organs11-13. Breast cancer, a heterogeneous disease, presents various pathological signs 
such as axillary lymph node metastasis (Figure 1.), which is associated with a high risk of 
recurrence and considered as an important prognosis factor in early stages of the disease14, 15. 
Several studies have tried to identify primary tumor signatures correlated to metastasis. Using 
microarray analysis, sets of prognostic genes (the Amsterdam signature, 70 genes, and the 
Rotterdam signature, 76 genes) were established that predicted the development of distant 
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Figure 1. Lymphatic system that filters the lymph fluid draining away from the breast area. The armpit, or 
"axilla" is the main lymph node area involved in breast cancer and two secondary lymph node areas are the internal 
mammary and supraclavicular regions.  
(Modified picture from    http://doctorstock.photoshelter.com/image/I0000u4cGX0VP_Do)  
Since the lymphatic system has a direct dispatch to spread primary tumor cells to the lymph 
nodes in breast cancer, primary tumor signatures have been considered as surrogates for lymph 
node metastasis. However, this persuasion has recently been controversial particularly in the 
context of transferring DNA methylation patterns from primary tumors to metastatic in breast 
cancer19-21. Considering that tumor dissemination is an early event in breast cancer 22, genetic 
and epigenetic analysis of tumors and metastatic lesions could provide results for biomarker 
discovery and may improve diagnosis, prognosis and proper management of treatment regimens 
in breast cancer patients. 
1.2    Breast neoplasm pathophysiology 
1.2.1    Hereditary breast cancer 
Breast cancer is a heterogeneous disease with sequential accumulation of molecular, 
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proportion of cases are susceptible of developing the disease by positive family history. 
Approximately 5-10% of cases are detected with BRCA1 and BRCA2 mutations. These two 
genes are conferred as high penetrance genes. Other high penetrance genes such as TP53 and 
PTEN are detected at lower frequencies in hereditary breast cancer 23-25. 
Over the last decade, it was increasingly demonstrated that harboring a germline mutation 
in BRAC1/2 genes increases the risk of breast cancer by 60-80% 26, 27. TP53 mutations are the 
cause of a rare autosomal dominant cancer predisposition referred to as Li–Fraumeni syndrome 
(LFS). LFS has approximately 1% prevalence among the hereditary breast cancer syndromes28.  
The other type of familial breast cancer syndrome, with less than 1% frequency, is known as 
Cowden syndrome (CS), which is associated with mutations in PTEN gene 29, 30. Along with 
BRAC1/2, P53 and PTEN mutations, CHEK2, ATM, BRIP1, and PALB2 were also identified as 
high frequency and low penetrance genes that are associated with the increased risk of breast 
cancer31-33. However, it was reported that more than 90% of breast cancers are independent of 
germline mutations34 and are primarily due to either somatic genetic or epigenetic alterations.  
1.2.2    Altered genes in sporadic breast cancer 
Genetic and epigenetic alterations on genes can change the quality (structure) or quantity 
(expression) of gene products as well as impairing specific cellular pathways that encouraged 
paying particular attention to them for identification of responsible alterations leading to 
tumorigenesis. 
Several studies on breast cancer cohorts have demonstrated the amplification and 
overexpression of several oncogenes such as: ERBB2, HER2 /neu, CCND1, MYC,	
   fibroblastic 
growth factors (FGFs) and their receptors, BCL2, CCNE, hTERT and H-ras 35-42. 
In addition to the amplification and overexpression of oncogenes, inactivation of tumor 
suppressor genes (TSGs) has been identified in breast tumorigenesis. Various mechanisms have 
been proposed for TSGs inactivation; point mutation of one allele and the LOH of the other 
allele are the most common cause of TSGs inactivation 43. The second mechanism involved in 
the loss or reduction of TSGs expression is DNA hypermethylation of CpG islands located in 
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aforementioned mechanism have been reported in sporadic breast cancer such as TP53, ATM, 
RB, BRCA1/2, CDH1, Cdksi (KIP, INK4), PTEN, ESR1 and IGFs 44.  Among the above tumor 
suppressor genes, TP53 and its signaling pathway have a central role in different cellular 
responses and have a potential role in cancer development. Loss of p53 function and impaired 
p53 signaling pathway have been reported in many types of cancer45. 
 
1.3    TP53 Tumor suppressor gene and protein structure 
The TP53 gene, located at 17p13.1, encodes the p53 protein, which has numerous 
function and protein-protein interactions. P53 has nine different isoforms originated from two 
distinct transcriptional start points as well as several alternative splicing patterns46. Studies on 
breast cancer cohorts indicated a correlation between mutation type and the clinical outcome of 
patients47. Therefore structure-function studies on wild type protein p53 are essential to 
understand functional consequences of mutations. 
Human p53 protein is 393-aa in length, which contains three domains flanked by proline-rich 
linker regions48. P53 domains consists of a transactivation domain (N-terminal region, 
residues1–62), a sequence-specific DNA binding domain (core region, residues 94–292) and a C-
terminal region that includes a tetramerization domain (residues 325–356) and a negative 
regulatory (residues 361–393) domain (Fig.1) 49. 
1.3.1    The transactivation domain 
The transactivation domain and its adjacent proline-rich region can activate p53 
transcription and regulate the cellular levels of p53, as well as, regulate p53 function and 
stability. Phosphorylation of the N-terminus can affect the stability of p53. This domain interacts 
with p53 regulators such as MDM2, a ubiquitin protein, that targets p53 for degradation and 









































































































































Figure 2. “Schematic view of the domain structure of p53. The columns indicate the relative frequency of 
cancer-associated mutations for each residue, data from the TP53 mutation database of the International 
Agency for Research on Cancer (version R10, www-p53.iarc.fr)49, 50” 
 
1.3.2    The DNA binding domain 
The core region binds to the double stranded DNA by recognizing the sequence 'half-site' motifs 
5'-Pu Pu Pu C (A/T) (T/A) G Py Py Py-3' (Pu=A/G, Py=T/C) which is separated by up to 13 
base pairs 54.  P53 regulates the cellular responses by stimulating transcription of many target 
genes in a selective manner. The affinity of binding p53 to its response elements is variable and 
depends on the recognition of the sequence. For example, this affinity is high for the genes 
involved in cell cycle arrest while it is low for the genes involved in apoptosis55, 56.   
1.3.3    The C-terminal domain  
The tetramerization domain regulates the oligomerization state of p53. It has been suggested that 
nuclear p53 levels might be controlled by its oligomerization state57.  The negative regulatory 
domain modulates p53 sequence-specific DNA binding by the core domain 22. Post-translational 
modifications of the C-terminus in response to cellular stress can activate p53 58 . However, 








































































































































1.4    Normal p53 functions 
P53 is a transcription factor with essential roles in diverse biologic activities.  P53 is 
activated in response to cellular stress, which is followed by targeting various genes and 
microRNAs and activating different pathways including cell cycle arrest, apoptosis, DNA repair 
and senescence. Activation of either of these pathways depends on the nature of the input stress 
signals that are interpreted by the upstream mediators of p53. For example, DNA double strand 
breaks or gamma radiation activates ataxia-telangectasia mutated (ATM) kinase and CHK2 
kinase, both kinases can phosphorylate p53. In addition, expression of oncogenes activate P14ARF 
that inhibits p53 degradation and increases levels of p53 protein 60. 
1.4.1    Down-stream events of the p53 Pathway 
1.4.1.1    Cell cycle arrest 
The activated p53 networks can inhibit cell cycle at G1 or G2 phases. Upregulation of 
p21, p53 target gene, inhibits cyclin dependent kinase which acts upon G1 to S phase in the cell 
cycle. On the other hand overexpression of 14-3-3 sigma (σ), a protein binds to CDC25C, 
contributes in blocking the G2 phase of the cell cycle61. 
1.4.1.2    Apoptosis 
The process of programed cell death can be regulated by different types of apoptotic 
pathways including the p53 pathway. Activated p53 induces expression of pro-apoptotic proteins 
such as Bax, Apaf1 and repressing expression levels of the anti-apoptotic proteins, Bcl-2 and 
Bcl-XL or survivin 62, 63. Indeed, translocation of p53 to the mitochondria enables interaction 
with Bcl-XL, which results in cytochorom c release to the cytoplasm 64.   
1.4.1.3   DNA repair 
 DNA damage can activate various repair mechanisms in cooperation with p53 via a post-
translational modification dependent manner 65. P53 modified proteins eventually elaborates a set 
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DNA repair 45. Recent evidence have indicated that p53 modulate transcriptional activity of 
nucleotide excision repair (NER) genes which promote the global genomic repair 66. Moreover, a 
potential role for p53 in base excision repair (BER) has been described, as BER deficiency in 
mutant p53 cells are found 67.  
1.4.1.4   Mitochondrial mass and function 
The integrity of mitochondrial function is necessary for various biosynthetic and 
bioenergetic pathways as well as the regulation of survival and death signals. Dysfunction and 
deregulation of mitochondria play an important role in the pathophysiology of cancers 68. 
Additionally, variations in mitochondrial DNA (mt-DNA) copy number, the both increase and 
decrease, have been strongly reported in different type of cancers 69, 70. 
In addition to its nuclear functions, p53 protein and its network have regulatory effect on 
mitochondria. Several genes encoding mitochondrial proteins are modulated by the 
transcriptional activity of p53 such as cytochorome-c oxidase 2 (SCO2), apoptosis-inducing 
factor (AIF), 16S rRNA and cytochorome-c oxidase (COX)71-73. Apart from regulatory role of 
p53 on mitochondrial proteins, it is also involved in mitochondrial biogenesis and copy number 
regulation through a direct interaction with mt-DNA polymerase gamma and mitochondrial 
transcription factor A (TFAM)74-76.  
Furthermore, p53 boosts mitochondrial genomic stability via stimulation of base excision 
repair77, 78. Human mitochondrial DNA mutation can be induced by generation of reactive 
oxygen species (ROS). An increase in mtDNA sensitivity to DNA-damaging oxidative stress, 
such as ROS, has been shown to be via deregulation of p53 protein in cancer cells74, 79.  MtDNA 
has a higher mutation rate than nuclear DNA, due to its closeness to the respiratory chain, lack of 
histone proteins and limited DNA repair capacity. Most of the mtDNA mutations occur in the D-
loop region, which is the major replication and transcription site of both the heavy and light 
strands of mtDNA80, 81. Previous studies have demonstrated that somatic mutation on the DNA-
binding domain of TP53 gene contributes to mtDNA mutation and mtDNA depletion which, 
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In contrast to the effects of p53 on mitochondria functional integrity, recent studies have 
revealed influences of mitochondrial dysfunction on p53 expression or function. These studies 
argued a potential functional decrease of p53 due to increases mitochondrial dysfunction 
according to Warburg effect in cancers83-85. Taken together, both P53 and mitochondria likely 
have reciprocal effect on each other, which may play an important role in pathogenesis of 
cancers. 
1.4.1.5   Senescence and telomere maintenance 
Senescence is the irreversible arrest of cell replication potency that occurs in response to 
different cellular stresses such as, unrepaired nuclear DNA damage or uncapped telomeres 86. 
Dysfunction of p53 (and its pathway) contributes to bypasses the senescence checkpoints which 
leads to telomere dysfunction in cancer87. Telomeres are specific repeat sequences (TTAGGG)n 
located at chromosome ends. They have a key role in the maintenance of chromosomal stability 
88. The TTAGGG repeats shorten with each cell division because of end replication mispairing, 
oxidative damage and other end processing events89, 90. Tumor cells have extremely short 
telomeres in association with increased genomic instability91, 92. This suggests that telomere 
changes are implicated in cancer development.  
Regulation of p16/Rb and p53/p21 pathways are important proliferation control 
mechanisms that are linked to telomere shortening in human cells93 . Inactivation of p53 enables 
continued proliferation of cells with dysfunctional telomeres, ultimately promoting chromosomal 
instability and transformation 94, 95 whereas expression of p16 inhibits phosphorylation of 
retinoblastoma protein (pRB), thus preventing cell-cycle progression 96. Recent data suggest that 
the severe genome instability present during telomere crisis, promotes secondary genetic changes 
that facilitate carcinogenesis97, 98. Several studies have also indicated that the up-regulation of 
p16 in senescent cells may be a consequence of telomere dysfunction 99 . This up-regulation of 
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1.5     Mechanism of p53 inactivation in cancer 
1.5.1   TP53 mutation 
The TP53 gene is often mutated in a vast majority of human cancers (over 50% of 
cancers) and most of these mutations are detected on the DNA binding domain60. The frequency 
of TP53 mutation outside the DNA binding domain is about 10%101 (Figure.2). TP53 mutations 
detected on the core region have been classified into two groups, I) replacing residues that 
contact DNA II) replacing residues responsible for DNA binding domain stabilization102.  The 
DNA binding domain is more susceptible to mutation due to the low melting temperature of this 
domain. It means every substitution in this part can influence protein folding103. In addition to 
the melting temperature, a high frequency of CG rich dinucleotides located on the DNA binding 
domain could contribute to the high frequency of mutation in this domain 104. 
 TP53 mutations are mainly missense mutation that could lead to new oncogenic 
functions or a gain of function (GOF). Many cancer studies have reported accumulation of GOF 
mutant p53 at a higher level in advanced stages of cancer. It is believe that this accumulation 
may promote a greater interaction with a larger subset of DNA motifs and proteins by the mutant 
p53 proteins compared to the wild type counterpart. The interaction of the mutant p53 protein is 
depended on its newly gained structure and affinities to DNA sequence and proteins 105. 
The frequency of TP53 mutations in breast cancer is approximately 20% and the 
frequencies are lower in node-negative patients (15-18%) than in node positive patients106, 107. 
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1.5.2    Molecular mechanism of p53 inactivation  
It has been estimated that dysfunction of the p53 pathway contributes to over 80% of 
human cancers 108.  The p53 pathway consists of hundreds of genes, involved in different 
biological outcomes. They interact with other signaling pathways and act as autoregulatory 
feedback loops following p53 activation 61, 109. P53 protein expression and function is tightly 
regulated by its autoregulatory feedback loops. In addition to regulatory loops impairing p53 
function and its downstream targets, epigenetic modifications and aberrant microRNA 
expression (targeting p53 pathway components) in cancer are two molecular mechanisms 
presumed to impair the p53 pathway. 
1.5.2.1    Changes in p53 auto-regulatory feedback loops 
The p53 feedback loops consist of proteins that are activated or expressed by p53 
activation that contribute to alter p53 expression level and activity. A variety of studies revealed 
seven negative feedback loops that down-regulate p53 activity. Three positive feedback loops 
have been detected that increase p53 activity. The core regulatory feedback loop is known as 
p53/MDM2/ p14ARF 45 (Figure 3.).  
Mdm2 inactivates the tumor suppressor p53 in response to stress by regulation the 
duration of p53 activity. Mdm2 binds directly to p53 to inhibit transcription and export p53 from 
the nucleolus to the cytoplasm, resulting in the degradation of p53 by ubiquitination 110, 111. The 
role of p14ARF in the p53 pathway is to indirectly regulate the level of p53 protein. The p14ARF 
protein inhibits degradation of p53 protein by keeping Mdm2 in the nucleolus and by restricting 
E3 ubiquitin protein111. 
The other important positive regulatory loop is PTEN/AKT that modulates p53 activity 
(Figure 3.). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is an essential 
component of the TP53 gene response upon DNA damage. Pten protein indirectly regulates p53 
function through keeping Akt inactive and making Mdm2 incapable of translocating into the cell 
nucleus for degradation of p53112, 113. More importantly, Pten prevents p53 degradation in the 
presence of Mdm2 by increasing p53-mediated transcription 112as well as binding to p53, leading 












































































































































Figure 3. P53 feedback loops. a) Core regulatory P14ARF / MDM2 loop, b) PTEN/AKT/ MDM2 loop. 
 
The P14ARF/MDM2/TP53 and PTEN pathways are the two critical TP53 control pathways, and 
alteration of either of these pathways can induce a variety of cancers and they are thus the focus 
of many breast cancer investigations115-120.  
 
1.5.2.2    Epigenetic Alterations 
Epigenetic alterations are recently recognized as one of the important features of human 
cancers. DNA methylation and covalent histone modifications are two major epigenetic 
modifications121, 122.   
DNA methylation of the cytosine located 5′ to a guanosine is one of the most important 
modifications of genomic DNA in eukaryotic cells. Methylation of cytosine at CpG 
dinucleotides is described as an epigenetic regulatory mechanism of genomic function that plays 
an important role in different biological processes including embryogenesis [1], genomic 
imprinting [2], X-chromosome inactivation, and cancer [3, 4]. DNA hypermethylation has been 
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function. This alteration has been known as epimutaion due to phenotypic similarities to genetic 
mutations123. 
The contribution of aberrant DNA hypermethylation of the transcriptional silencing and 
carcinogenesis of cancer related genes has been demonstrated in different cancer types22, 124. The 
methylation profile of genes involved in critical molecular processes such as cell cycle control, 
DNA repair and angiogenesis in breast cancer has been investigated20, 21, 125, 126. Promoter 
hypermethylation of the p53 pathway in cancers with low frequency of TP53 mutations have 
been identified and suggested that malfunction of p53 can be mediated via an epigenetic 
mechanism70, 127. 
 
1.5.2.3  Aberrant microRNA expression 
miRNAs are a class of small non-coding regulatory RNA, which is synthesized by RNA 
polymerase II. Mature miRNAs, 19-25 nucleotide in length are associate with RNA-induced 
silencing complex (RISC) and bind to the complementary protein coding messenger RNA 
(mRNA) target that eventually mediates gene expression modulation 128. Several reports have 
demonstrated important roles for miRNA in different biological processes. Recently aberrant 
expression of miRNAs has been indicated to the pathogenesis of different human cancers 129-131. 
These deregulated miRNAs contribute functionally to the initiation and progression of cancer by 
altering the expression of crucial pathways involved in cell proliferation and survival132, 133.  
Numerous studies have been directed toward understanding the cross talk between P53 
transcription regulation and miRNAs. The impact of miRNAs in the dysregulation of p53 and its 
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1.6    Biomarkers 
Biomarkers are substances found in biological fluid or tissues, which are differentially in 
disease and normal states. Biomarkers are typically associated to pathogenic processes or to 
pharmacologic responses following treatment135 . These can be indicated as single nucleotide 
polymorphisms (SNPs), DNA methylation, changes in mRNAs or miRNAs, protein and 
metabolite levels. Cancer biomarkers can be divided into three categories136 : (a) Diagnostic 
(classification) biomarkers are used to detect and identify a given type of cancer in an individual. 
This type of biomarker is expected to have high levels of diagnostic sensitivity and specificity. 
(b) Prognostic biomarkers are commonly used once the disease status has been established. (c) 
Stratification (predictive) biomarkers can serve to predict the likely response to a drug before 
starting treatment, thus classifying individuals as responders or non-responders16. 
The candidate biomarkers should have very high specificity and sensitivity (close to 
100%) to be accepted for clinical utility. In addition, they need to be economical, easy to 
measure and reproducible by different methods. So far only a few biomarkers have been 
approved by the Food and Drug Administration (FDA) 69. Moreover, there are remarkable 
limitations for the implementation of the huge number of biomarker candidates represented in 
the majority of reports. These limitations mainly lie in the lack of technical validation, the low 
number of patient and control subjects in a study, and the inability to select a cohort with the 
same clinicopathological characteristics.  
The most important biomarkers for breast cancer prognosis and therapy are Estrogen 
Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth factor Receptor (HER2), 
Cancer-Antigen 15/3 (CA-15-3) or Cancer-Antigen (CA-27-29), Cytokeratins and Oncotype DX  
137.  Considerable progress has recently been made in exploring components of the pathways 
linked to tumorigenesis. Increasing our knowledge of specific biologic pathways related to the 
initiation and progression of cancer can lead to the development of novel biomarkers for early 
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2.     AIM OF THE STUDY 
Mechanism of p53 inactivation independent of TP53 mutations in breast cancer leading to 
biomarker discovery 
The frequency of TP53 mutations in breast cancer is lower than that of many other cancers. 
Other than TP53 mutation, alteration of upstream and/or downstream TP53 regulators 
(autoregulatory loops, proteins and miRNAs) is another potential mechanism, which could 
modulate the inactivation and suppression of this gene and its signaling pathway in breast cancer. 
These alterations might provide further clue to establish meaningful biomarkers for breast cancer 
patients. Therefore, to find the molecular mechanism involved in tumor suppressor p53 protein 
deregulation independent of mutation: First, we assessed the aberrant methylation of CpG islands 
of genes involved in two autoregulatory feedback loops (P14ARF/MDM2/TP53 and PTEN) in 
breast cancer patients, as well as evaluating each hypermethylated CpG sites to the recognition 
sites of the transcription factors along the promoter region. The possibility of using 
hypermethylated genes in serum samples as a blood-based test fro breast cancer was explored. 
Second, considering aberrant DNA hypermethylation is a reversible alteration, on the basis of 
demethylation therapy and in-silico pathway analysis the over-all proteomic characterization of 
breast neoplasm in the presence or lack of TP53 mutation were identified. Third, aberrant 
expression of miRNAs impairing the p53 pathway depending on p53 status in breast cancer has 
been characterized. 
 
The Relationship between aberrant DNA methylation of p53 related pathways and 
downstream events  
Activated p53 targets many genes and regulates several biologic processes including telomere 
and mitochondria maintenance. A certain telomere length and normal mitochondrial function are 
necessary for genomic stability and cellular integrity. Thus, shortened telomere length and 
mitochondria dysfunctions are the focus of many cancer investigations and are suggested to play 













































































































































  [AIM OF THE STUDY] 
	
  
Taken together, these can provide new insights into epigenetic silencing of some of the 
regulatory pathways, leading to the deregulation of p53 protein, which most probably influences 
on the telomere length shortening and on the mtDNA vulnerability in breast cancer. In this 
context, we investigated a potential link between promoter hypermethylation of the TP53/P21 
and P16/Rb genes and telomere length shortening. The correlation of aberrant methylation 
patterns of P14ARF/MDM2/TP53/PTEN and mtDNA alteration, including D-loop region integrity 
and mtDNA content were also studied. Lastly, the study was extended to understand the link 
between the p53 pathway and epigenetic alterations by treating breast cancer cell lines with a 
demethylating agent, 5-aza-2′-deoxycytidine. Using LC-MS-MS analysis, proteins influenced by 
alteration in DNA methylation status were identified. Additionally, a comprehensive in-silico 
pathway analysis was performed to characterize biological responses that allowed us to detect 
aberrant proteins expression involved in mitochondrial function and in telomere maintenance in 
breast neoplasm.  
 
Contributions of aberrant DNA methylation signature of primary tumor to metastatic 
lesion 
The aberrant hypermethylation of genes involved in critical molecular processes e.g. cell cycle 
control, DNA repair and angiogenesis in primary breast cancer has been a center of attention in 
many studies. However, the DNA methylation profile of metastatic tumors in breast cancer 
patients is less characterized and poorly understood. In a previous study of our group, 
methylation signatures of 42,528 CpG sites from 22 breast cancer candidate genes demonstrated 
promoter hypermethylation in 10 genes. Our assessment of the DNA methylation status of genes 
involved in two p53 autoregulatory feedback loops revealed hypermethylation of two genes in 
those loops. Here, we further analyzed the contribution of significant aberrant methylation 
profile of twelve cancer related genes from the aforementioned studies (APC, BIN, BMP6, 
BRCA1, CST6, ESR-b, GSTP1, P14, P16, P21, PTEN and TIMP3) in metastatic axillary lymph 
nodes in comparison to the primary tumor tissues and the adjacent normal tissues from the same 
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3. PEER-REVIEW AND UNDER -REVIEW MANUSCRIPTS 
3.1. Published review article 
Specificity of methylation assays in cancer research: a guideline for designing primers and 
probes 
Authors: Zeinab Barekati, Ramin Radpour, Corina Kohler and Xiao Yan Zhong 
Journal: Obstetrics and Gynecology International. 2010, pii: 870865 
Summary:  Technically for applying DNA methylation alterations as a biomarker, certain 
specificity and sensitivity needed to be defined. This review focuses on important criteria for 
designing specific primer pairs and probe to avoid false positive detection of DNA methylation 
profiles. Indeed, some information about related online web tools is provided. 
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3.2 Published research article: 
Correlation of telomere length shortening with promoter methylation profile of p16/Rb and  
p53/p21 pathways in breast cancer 
Authors: Ramin Radpour*, Zeinab Barekati*, Mahdi Montazer Haghighi, Corina Kohler, Reza      
Asadollahi, Peyman Mohammadi Torbati, Wolfgang Holzgreve and Xiao Yan Zhong. 
Journal: Modern Pathology. 2010, 23(5): 763-72 
Summary: Relative telomere length and its potential correlation with methylation status of 
TP53, P21 and P16 promoters in breast cancer patients have been investigated. The results 
demonstrated a significant shortening of telomere regions in tumour tissues compared with 
adjacent normal tissues, which correlated with a different level of hypermethylation in the TP53, 
P21 and P16 promoters. Shortened telomere and promoter hypermethylation of related genes 
have potential to be served as breast cancer biomarkers. 
Author contributions: Zeinab Barekati was involved in performing the experiment, data 
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3.3 Published research article: 
Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer 
patients lacking TP53 mutations 
Authors: Zeinab Barekati, Ramin Radpour, Corina Kohler, Bei Zhang, Paolo Toniolo, Per 
Lenner, Qing Lv, Hong Zheng and Xiao Yan Zhong 
Journal: Human Molecular Genetics. 2010, 1; 19(15): 2936-46. 
Summary: The present study investigated promoter hypermethylation of TP53 regulatory 
pathways, P14ARF/MDM2/TP53/PTEN, providing a potential link between epigenetic changes 
and mitochondrial DNA alterations in breast cancer patients lacking a TP53 mutation. The 
possibility of using the cancer-specific alterations in serum samples as a blood-based test was 
also explored. Our finding showed association between two hypermethylated genes,  P14ARF and 
PTEN,  and mtDNA depletion as well as high frequency of somatic mutation in the tumour 
tissues compared to the matched normal tissues. Taken together these data provides an insight 
into understanding of p53 dysfunction based on the epigenetic silencing of the crucial genes 
involved in autoregulatory loops. Additionally, release of significant aberrant methylated PTEN 
in matched serum samples could suggest a promising biomarker for breast cancer. 
Author contributions: Zeinab Barekati was involved in experimental design, performing the 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Published research article: 
Methylation Signature of Lymph Node Metastases in Breast Cancer Patients 
Author: Zeinab Barekati, Ramin Radpour, Qing Lu,	
  Johannes Bitzer, Hong Zheng, Paolo 
Toniolo, Per Lenner, Xiao Yan Zhong	
  
Journal: BMC Cancer 
Summary: Invasion and metastasis are important hallmarks of malignant tumours caused by 
complex genetic and epigenetic alterations. DNA methylation profile of twelve cancer related 
genes were assessed to identify a potential metastatic signature of them. These genes were 
selected from the previous studies in our group. The results of the present study showed 
methylation heterogeneity between primary tumors and metastatic lesion. The contribution of 
aberrant methylation alterations of BMP6, BRCA1 and P16 genes in metastatic lymph nodes 
suggests implementing these genes as markers for screening metastasis. 
 
Author contributions: Zeinab Barekati was involved in experimental design, performing the 
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3.5 Under-review manuscript 
Proteomics Investigation to Identify p53-Associated Proteins Upon Demethylation 
Treatment in the Presence or Lack of TP53 Mutation 
Author: Zeinab Barekati, Ramin Radpour, Corina Kohler, Thomas Grussenmeyer, Paul Jenoe, 
Martin M. Schumacher, Suzette Moes, Frank Staedtler, Xiao Yan Zhong, Ivan Lefkovits. 
Summary: The contribution of aberrant DNA hypermethylation in gene silencing and 
carcinogenesis has been demonstrated. DNA hypermethylation is a reversible alteration. Here, on 
the basis of demethylation therapy and in-silico pathway analysis we achieved an over-all 
proteomic characterization of wild type and mutant p53 breast neoplasm. Our founding might 
provide a further clue to establish meaningful biomarkers for breast cancer patients. 
 
Author contributions: Zeinab Barekati was involved in experimental design, performing the 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.6 Under-review manuscript 
Dysregulation of P53 Pathway-Associated microRNAs in Breast Cancer  
 
Author: Zeinab Barekati, Ramin Radpour, Martin M. Schumacher, Nicole Hartmann, Fabio levi, 
Paolo Toniolo, Per Lenner, Frank Staedtler, Xiao Yan Zhong	
  
Summary: Present study investigated differentially expressed miRNAs that led to dysregulation 
of the p53 signaling pathway in breast cancer. The results reported in this study increase the 
understanding of impaired p53 pathway by miRNAs in human breast cancer. 
 
Author contributions: Zeinab Barekati was involved in experimental design, performing the 
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4. SUMMARY OF THE RESULTS 
4.1 Mechanism of p53 inactivation independent of TP53 mutations 
4.1.1 Quantitative methylation profiles of the p53 auto-regulatory feedback loops  
 We analyzed the methylation patterns of P14ARF/MDM2/TP53 and PTEN in 66 triple-matched 
samples (cancerous tissues, matched normal tissues and serum samples) from 22 wild type p53 
(wt- p53) breast cancer patients. For all the genes, one amplicon per gene and in total 117 CpG 
sites per sample (total of 7020 sites in 66 analyzed samples) were analyzed (Table 1 and 
Supplementary Material 3; section 3.3).  Hierarchical cluster analysis profiling of the promoter 
alterations of the four studied genes is shown in Figure 2A (Section 3.3).  
The quantitative methylation profiling of MDM2 oncogene and TP53 for both the tumor and the 
normal tissues showed a relatively comparable methylation pattern whereas P14ARF and PTEN 
presented significantly higher methylation levels in tumor tissue versus normal tissue (P <0.05 
and P <0.01, respectively). Indeed, the PTEN methylation pattern was significantly higher 
methylated in the matched serum samples than the normal tissues and it showed significant 
concordance to methylation profile of the tumor tissues (Spearman’s rho test; P < 0.05).  
The comparison of methylation ratio between the aforementioned genes and their upstream 
regulatory sequence revealed pronounced accumulation of hypermethylated CpG sites around 
TATA box region in tumor-derived samples. In serum and normal samples, methylated CpG 
sites were randomly distributed on 5’-UTRs of the studied genes (Fig. 2C; section 3.3). 
 
4.1.2. The p53-associated proteins upon demethylation treatment  
A proteome-based approach in three breast cancer cell lines (MCF7, HS578T and BT549) was 
performed after treatment with an optimal dosage of 5-aza-2′-deoxycytidine (DAC) and in-silico 
pathway analysis to find out methylated genes with potential link to the P53 pathway. Here, we 





























































































































  [SUMMARY OF THE RESULTS] 
	
  
For MCF7, a total of 12 differentially expressed protein spots were detected and 22 proteins were 
eventually identified by LC-MS-MS analysis (Table 2 and 3; Section 3.4).  The in-silico pathway 
analysis demonstrated three up-regulated proteins, 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP cyclohydrolase (Atic), calreticulin precursor (Calr) and 
proliferating cell nuclear antigen (Pcna), which has regulatory role on p53 (Fig.1; Section 3.4). 
4.1.3 Aberrant expression of miRNAs impairing p53 pathway 
The Gene expression results obtained from Microarray chip were analyzed according to the p53 
status of the three studied breast cancer cell lines (MCF7, HS578T and BT549). The comparison 
of miRNA expression profiling of the wt-p53 breast cancer cell line (MCF-7) and mutant p53 
breast cancer cell lines (BT549, HS578T) revealed in total 59 differentially expressed miRNAs 
(≥2 fold change).  Indeed, The mRNA expression profiles of the p53 signaling pathway were 
measured in the three breast cancer cell lines and followed by in-silico pathway analysis of 
differentially expressed miRNAs. The results displayed association between six differentially 
expressed miRNAs (miR-125b, miR-15a, miR155, miR-16, miR-183 and miR-21) and 
dysregulation of  BCL2, CDC25A, MLH1, MSH2, PRKCA1, TP53, SESN. 
Furthermore, the six characterized miRNAs were analyzed in 30 pairs clinical specimens (tumor 
tissues and matched normal tissues) of breast cancer patients. The results showed significant 
down-regulation of miR-125b and significant up-regulation of miR-21 in the tumor tissues 
compared to the normal matched tissues in a TP53-dependent expression manner for miR-21 
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4.2 The relationship between aberrant DNA methylation of p53 related pathway and 
downstream events 
4.2.1 Telomere length shortening and promoter methylation profile of p16/Rb andp53/p21 
pathways 
For this part, 52 paraffin-embedded breast cancer tissues and 52 paired matched normal tissues 
were subjected to study. The telomere length in cancer tissues was significantly lower than that 
in normal tissues (Mann–Whitney U-Test; P<0.001). Quantitative methylation analysis has been 
performed for TP53, P21and P16 genes. One amplicon per gene and 83 CpG sites per sample 
(4316 CpG sites in total) have been analyzed. The results showed significant correlation between 
the telomere length shortening in cancer tissues and  methylation proportion of TP53, P21 and 
P16 (r=-0.33, P=0.001; r=-0.70, P<0.0001 and r=-0.71, P<0.0001; respectively) (Figure 4; 
Section 3.2). 
4.2.2 Mitochondrial DNA alterations and promoter methylation profile of 
TP53/P14ARF/MDM2 and PTEN  
We assessed Mitochondrial DNA (mtDNA) damage including D-loop region integrity and 
mtDNA content in breast cancer patients lacking TP53 mutation. In this context, direct 
sequencing was performed to analyze D-loop region and the results showed somatic mutations in 
36.36% (8 of 22) of studied cancerous samples. The prevalence of detected germline mutations 
in the D-loop region was markedly higher at 90.91% (20 of 22) than somatic mutations and with 
mostly multiple germline mutations in each case. The details of the prevalence of germline and 
somatic mutations are provided in Table 2, and the spectrum of the mutation along the length of 
the D-loop is illustrated in Figure 3 (Section3.3). The mtDNA contents were significantly lower 
in the cancer tissues than the normal tissues, with 11.88-fold changes (P< 0.01). In this part of 
the study we found association between higher methylation proportions of P14ARF and PTEN in 































































































































  [SUMMARY OF THE RESULTS] 
	
  
4.2.3 The potential link between the p53-associated proteins upon demethylation treatment 
and mitochondria or telomere maintenance 
The proteomics study of the three breast cancer cell lines (MCF7, HS578T and BT549) after 
treatment with an optimal dosage of DAC and in-silico pathway analysis revealed aberrant 
expression of thioredoxin-dependent peroxide reductase (Prdx3) and proliferating cell nuclear 
antigen (Pcna) that are linked to mitochondria and telomere maintenance, respectively.  The 
dysregulation of Prdx3 has been found in a p53-dependent status since it was up-regulated in 
BT549 (mutant p53) cell line and down-regulated in MCF7 (wt-p53) cell line. The 
overexpression of Pcna protein, involves in telomere maintenance, was detected in MCF7 cell 
line. 
 4.3 Contributions of aberrant DNA methylation signature of primary tumor to metastatic 
lesion  
In the current part of the study, methylation ratio on promoter region of APC, BIN1, BRCA1, 
BMP6, CST6, ESR-b, GSTP1, P14, P16, P21, PTEN and TIMP3 were quantified in matched 
primary tumors tissues, matched normal tissues and lymph node metastasis of 24 breast cancer 
patients. For all the genes, one amplicon per gene and 250 CpG sites in total per sample (total of 
16,250 sites in 65 analyzed samples) were analyzed (Table 2; Supplementary data 2; Section 
3.6). The methylation proportions of APC, BIN1, BMP6, BRCA1, CST6, ESR-b, P16, PTEN and 
TIMP3 were significantly higher in primary tumor tissue versus matched normal tissue (P<0.05). 
Comparison of methylation statuses of the 12 breast cancer candidate genes in the paired lymph 
node metastasis to the matched normal tissue showed significantly higher methylation levels for 
APC, BMP6, BRCA1 and P16 genes (P<0.05).  
The molecular function, biological processes and contribution of the studied genes to 
developing metastasis were analyzed by ResNet® 7 (Mammal). The pathway analysis revealed 
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5.    FINAL DISSCUSSION AND CONCLUSION 
The tumor suppressor gene p53 has an important role in prevention of neoplastic development by 
regulation of cell cycle progression and apoptosis as well as maintaining genetic stability in 
response to cellular stress1, 2. Loss of p53 function and impaired p53 signaling pathway have 
been reported in many types of cancer3. Dysfunction of p53 mostly reported to be attributed by 
mutation; however, alterations of upstream and/or downstream regulatory factors could be 
another plausible mechanism for inactivation of p53 and impairing the p53 signaling pathway in 
breast cancer. To find molecular mechanisms involved in dysregulation of p53 in breast cancer 
independent of mutation, we assessed DNA methylation on promoter regions of the p53 auto-
regulatory feedback loops (P14ARF/MDM2/TP53 and PTEN). Indeed, dysregulated proteins and 
miRNAs, which could impair p53-signaling pathway in breast cancer, were characterized. The 
down-stream events in relation to p53 pathway such as mtDNA and telomere length shortening 
were studied as well. Furthermore, the contribution of aberrant DNA methylation signature of 12 
cancer related genes from primary tumor to matched lymph node metastasis were explored in a 
patient cohort consisting of invasive ductal carcinoma. 
Investigation of DNA methylation profiles of the p53 auto-regulatory feedback loops 
revealed significant hypermethylation on promoter regions for P14ARF and PTEN tumor 
suppressor genes (P<0.05), in which hypermethylated CpG sites accumulated around TATA box 
region. A frequent aberrant methylation patterns of P14ARF and a down-regulation of this tumor 
suppressor gene have been reported in previous breast cancer studies 4, 5. The hypermethylation 
of PTEN has also been found in breast carcinoma, which resulted in expression repression of a 
subset of breast cancers 6-8. Indeed, the significant high methylation proportion of PTEN in 
matched serum samples and its concordance to the tumor tissues (P<0.05), proposed a possible 
use of this gene as a marker in development of blood-based tests. Taken together, present data 
suggest that the dysregulation of p53 possibly occur by suppression of P14ARF and PTEN 
expressions, which emphasizes on the importance of an epigenetic alteration-mediated silencing 
in the p53 auto-regulatory feedback loops. 
Our further investigation regarding involvement of DNA hypermethylation in 
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cell lines (BT549, HS578T and MCF7) and in-silico pathway analysis, led us to characterize 
over-expression of Atic, Calr and Pcna proteins with regulatory role on p53 in wt-p53 breast 
cancer cell line (MCF7). These proteins regulate p53 function by different mechanisms; Atic has 
positive regulatory effect on p53 expression and phosphorylate p53 that leads to regulate cell 
growth and induction of apoptosis 9, 10. Calr function is required for regulation and nuclear 
localization of the p53 protein and it also plays a role in inhibition of cancer metastasis 11, 12. 
Pcna contributes to p53 stabilization via posttranslational modification13, 14. The low expression 
of Atic, Calr and Pcna in un-treated MCF7 might be explained by DNA hypermethylation, which 
was contributed to transcriptional silencing and eventually to down-regulation of protein 
expression.  
The comparison of miRNA expression profiling of the wt-p53 breast cancer cell line 
(MCF-7) and mutant p53 breast cancer cell lines (BT549, HS578T) along with their interactions 
to the p53 signaling pathway, revealed differential expression for miR-125b, miR-15a, miR155, 
miR-16, miR-183 and miR-21, which could be suggested as p53 pathway disruptors in breast 
cancer. The previous studies in solid tumors defined different roles for these six dysregulated 
miRNAs in cancer such as in neoplasm progression (miR-125b, miR-15a and miR-16), invasion 
and metastasis (miR-155, miR-183 and miR-21) and they are also suggested to have prognostic 
values in cancer15-19.  Our investigation on miRNAs disruptor in clinical specimens revealed 
significant dysregulation of miR-125b and miR-21 in the tumor tissues compared to the normal 
matched tissues (P<0.05) with TP53 status-dependent manner for miR-21 (P<0.05). The down-
regulation of miR-125b was inline with previous reports in breast cancer 20-22. The pathway 
analysis presented regulatory connection between miR-21 and TP53, however, the binding site 
on the p53 mRNA for miR-21 has not yet been characterized and regulation of p53 by miR-21 or 
vice versa is a controversial issue 23, 24 and needed to be investigated in more depth. 
To determine the mechanistic link between inactivated p53 related pathways through 
epigenetic silencing and the actual down-stream alterations in cancer kinetics, we assessed 
telomere length shortening and mtDNA damages, including D-loop region integrity and mtDNA 
content, in breast cancer patients. The telomere length and promoter methylation status of the 
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that the average telomere length in breast cancer tissue was significantly shorter than that in the 
adjacent normal tissue, (P<0.001). Indeed, hypermethylation of TP53, P21 and P16 promoters 
significantly correlated with shortened telomere length in the cancer tissues (P<0.001). In 
general, malignant tumors show shorter telomeres than corresponding normal tissue, and 
telomere dysfunction has been indicated as a negative prognostic marker in solid tumors, 
including breast cancer 25, 26. Telomere shortening in primary human cells leads to replicative 
senescence, which is regulated in part by effectors in the P16/Rb and/or TP53/P21 pathways 27-
29. As well, p53/p21-mediated DNA damage signals are elicited by telomere dysfunction. 
However, there is still considerable debate on the exact role of telomere attrition on the P16 
pathway during senescence. Taken together, these findings suggest that P16 and P53/P21 may 
act as a gatekeeper to prevent critical telomere shortening and genome instability.  
A part from aberrant DNA methylation and telomere length shortening, we found 
considerable mtDNA damage in tumor tissues, which was associated with the hypermethylated 
p53 auto-regulatory feedback loops (P14 ARF and PTEN).  Our data presented a high rate of D-
loop region mutations (36.36% somatic and 90.91% germline mutations) in breast cancer 
patients. Association of TP53 alteration with mtDNA damage has been reported in a breast 
cancer patient 30. Moreover, significant mtDNA depletion in the tumor tissues compared to the 
normal tissues has been found in our study (P< 0.01). It has been demonstrated that the depletion 
of mtDNA resulted from a loss of p53 function 31. The mtDNA damage in the studied cohort, D-
loop mutations and mtDNA depletion, might be explained by the indirect effect of p53 
inactivation, P14ARF and PTEN hypermethylation, on mtDNA vulnerability.   
Aberrant methylation profiles and silencing of only a small subset of tumor suppressors and 
cancer related genes in both the primary tumor and lymph node metastasis has been investigated 
for breast cancer 32-35. We implemented the methylation signature of the 12 breast cancer 
candidate genes (APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14, P16, P21, PTEN and 
TIMP3) by comparing lymph nodes metastasis to their matched primary tumor tissues and 
normal tissues from the same breast cancer patients. The quantitative methylation analysis of the 
12 studied genes in the present cohort showed higher methylation proportion for the primary 
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BMP6, BRCA1, CST6, ESR-b, P16, PTEN and TIMP3 promoter regions (P<0.05, P<0.05, 
P<0.01, P<0.0001, P<0.01, P<0.01, P<0.05, P<0.05, P<0.01; respectively). Among the analyzed 
genes, APC, BMP6, BRCA1 and P16 showed higher methylation proportions in matched lymph 
node metastasis than the normal tissues (P<0.05 and P<0.01, P<0.0001, P<0.05; respectively). 
Present findings provided evidence of differences in methylation status between primary tumors 
and their corresponding matched lymph nodes and demonstrated methylation heterogeneity 
between primary tumors and metastatic lesion which are in line with previous reports described 
about primary tumor and metastasis in breast, gastric and colorectal cancers36-38. The pathway 
analysis revealed that BMP6, BRCA1 and P16 have a role in prevention of neoplasm metastasis 
(Fig.3).  The relation of DNA methylation for BRCA1 and P16 with tumor recurrence has been 
reported with a high value in breast cancer patients39. Moreover, association of P16 
hypermethylation with cancer progression and lymph node invasion has been shown in different 
studies40, 41. The aberrant methylation signatures of these genes found in the metastatic lymph 
node could be serving as markers for screening metastasis in breast cancer. 
In conclusion, the results reported in this study increase the understanding of p53 
inactivation and impaired p53 pathway in wt-p53 breast cancer and our finding might provide a 
further clue to establish meaningful biomarkers, which could improve prognosis and therapeutic 
management of the breast cancer patients. Thus, we suggest aberrant methylation alterations of 
APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14ARF, P16, P21, PTEN and TIMP3 as well 
as overexpression of miR-21, mtDNA damage and shortened telomere length as tumor specific 
biomarkers in breast cancer. The contribution of aberrant methylation alterations of BMP6, 
BRCA1 and P16 genes in lymph node metastasis suggests implementing these genes as markers 
for screening metastasis for breast cancer patients. Such biomarkers will be needed to be 
additionally explored for the potential opposing functional effects of specific hypermethylated 
CpG sites on transcriptional activity as well as for absolute percent methylation cutoffs for each 
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